{{medical}}
[[File:3CS9_Abl1_Nilotinib.png|右]]（紅）作用在Abl激酶（藍）之上。尼罗替尼是用來治療[[慢性骨髓性白血病|慢性骨髓性白血病]]，一種血液科惡性疾病的藥物。]]

'''酪氨酸激酶抑制劑'''（Tyrosine kinase inhibitor，TKI）是能阻斷[[酪氨酸激酶|酪氨酸激酶]]的藥物。由於酪氨酸激酶在細胞內擔任許多訊號傳遞的開關，因此該酶的突變常常引起癌症；酪氨酸激酶抑制劑因此通常做為癌症藥物使用。

酪氨酸激酶抑制劑也被稱為「Tyrphostins」，也就是 「[[酪氨酸|酪氨酸]][[磷酸化|磷酸化]][[酶抑制剂|抑制劑]]」（Tyrosine Phosphorylation Inhibitor）的縮寫，起源於一份1988年的論文。<ref>{{cite journal|title=Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors|journal=Science|issue=4880|doi=10.1126/science.3263702|year=1988|volume=242|pages=933–935|bibcode=1988Sci...242..933Y|pmid=3263702|vauthors=Yaish P, Gazit A, Gilon C, Levitzki A}}</ref> 該論文是第一篇描述抑制[[表皮生长因子受体|表皮生長因子受體]]（EGFR）之催化活性的文章。

該研究也是第一個透過系統性的搜尋而發現針對酪氨酸磷酸化的小分子抑制劑。該抑制劑不干擾其他磷酸化[[絲氨酸|絲氨酸]]與[[蘇氨酸|蘇氨酸]]的[[蛋白激酶|蛋白激酶]]，也不影響其他具有類似功能的蛋白質，例如胰島素受器的磷酸化[[結構域|結構域]]。研究更發現儘管各種酪氨酸激酶的結構域都有高度的保留性（即高度相似），設計精良的藥物仍能分辨不同的蛋白質並予以抑制，例如EGFR和[[HER2/neu|HER2]]。 <ref>{{cite journal|title=Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases|journal=J Med Chem|issue=6|doi=10.1021/jm00110a022|year=1991|volume=34|pages=1896–907|pmid=1676428|vauthors=Gazit A, Osherov N, Posner I, Yaish P, Poradosu E, Gilon C, Levitzki A}}</ref><ref>{{cite journal|title=Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins|journal=J Biol Chem|issue=15|year=1993|volume=268|pages=11134–42|pmid=8098709|vauthors=Osherov N, Gazit A, Gilon C, Levitzki A}}</ref>

== 藥物發展 ==
目前已經開發了許多酪胺酸激酶抑制劑，以作為抗腫瘤藥和白血球抑制劑<ref>{{cite journal|title=Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate|journal=Blood|issue=12|year=1993|volume=82|pages=3524–9.|pmid=7505115|vauthors=Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A}}</ref><ref>{{cite journal|title=Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor|journal=Nature|issue=6566|doi=10.1038/379645a0|year=1996|volume=379|pages=645–8|bibcode=1996Natur.379..645M|pmid=8628398|vauthors=Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM}}</ref>。例如被用來治療[[慢性粒细胞性白血病|慢性骨髓性白血病]]的[[伊马替尼|伊马替尼]]（Imatinib）<ref>{{cite journal|title=Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells|journal=Nat Med|issue=5|doi=10.1038/nm0596-561|year=1996|volume=2|pages=561–6|pmid=8616716|vauthors=Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB}}</ref>；稍晚有[[吉非替尼|吉非替尼]]（Gefitinib）和[[厄洛替尼|厄洛替尼]]（Erlotinib），以EGFR作為目標蛋白。利用早期針對[[血管内皮生长因子|VEGF]]受器的研究所開發的[[舒尼替尼|舒尼替尼]]（Sunitinib）也被用於抑制[[成纤维细胞生长因子|FGF]]、[[血小板衍生生長因子|PDGF]]、VEGF等蛋白。<ref>{{cite journal|title=Flk-1 as a target for tumor growth inhibition|journal=Cancer Res.|issue=15|year=1996|volume=56|pages=3540–5|pmid=8758924|vauthors=Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK}}</ref>

== 藥物機轉 ==
不同的酪氨酸激酶抑制劑有不同的作用方式。抑制劑能和[[三磷酸腺苷|三磷酸腺苷]]、[[受質|受質]]等競爭，也可以透過[[别构调节|異位調控]]引起激酶的[[構象改變|構形改變]]<ref>{{cite journal|title=Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program|journal=Mol. Pharmacol.|issue=4|year=1994|volume=45|pages=673–83|pmid=8183246|vauthors=Posner I, Engel M, Gazit A, Levitzki A}}</ref>；甚至能讓酪氨酸激酶無法接上維持其穩定性的[[分子伴侣|伴護蛋白]] Cdc37-Hsp90，進而導致激酶被[[泛素|泛素化]]並降解。<ref>{{cite journal|title=ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system|author=Polier|journal=Nture Chem Biol|issue=5|doi=10.1038/nchembio.1212|year=2013|volume=9|pages=307–312|pmid=23502424|display-authors=etal}}</ref> 原則上，此藥物也能應用在非癌症的增生性疾病（Proliferative disease）及發炎反應上<ref>{{cite journal|title=Tyrphostins and other tyrosine kinase inhibitors|journal=Annu Rev Biochem|doi=10.1146/annurev.biochem.75.103004.142657|year=2006|volume=75|pages=93–109|pmid=16756486|vauthors=Levitzki A, Mishani E}}</ref>，不過目前還沒有類似的應用。

== 參考文獻 ==
{{reflist|2}}

== 參見 ==
* {{Le|Bcr-Abl酪胺酸激酶抑制劑|Bcr-Abl tyrosine-kinase inhibitor}}
* {{Le|蛋白質激酶抑制劑|Protein kinase inhibitor}}
*[[生長因子受體|生長因子受體]](Growth factor receptor)

==外部連結==
* {{MeshName|Protein+kinase+inhibitors}}
* [https://web.archive.org/web/20070517125440/http://www.reactionbiology.com/pages/kinase.htm IC50 values for common inhibitors]
* [https://web.archive.org/web/20080609221941/http://kinasecentral.com/ KinaseCentral.com]
* [http://www.nature.com/nrd/journal/v8/n9/fig_tab/nrd2871_T1.html "Chemical structures and known kinase targets for clinically approved kinase inhibitors" Nature.com]

{{Extracellular chemotherapeutic agents}}
{{Enzyme inhibition}}
{{Growth factor receptor modulators}}

[[Category:酪氨酸激酶抑制剂|Category:酪氨酸激酶抑制剂]]